Conservative Treatment with Adjunctive Use of Teriparatide for Periprosthetic Humeral Fractures after Reverse Total Shoulder Arthroplasty: A Report of 6 Cases Authors: Hyuk-Joon Sohn, Bum-Soon Park, Junkyung Hwang, Jong Pil Yoon, Jin-Young Bang, Chul-Hyun Cho Published: 2026 ABSTRACT AbstractBackgroundPeriprosthetic humeral fractures (PPHFs) after reverse total shoulder arthroplasty (RTSA) are challenging complications, particularly in elderly patients with osteoporotic bone and multiple comorbidities. Although surgical treatment is commonly recommended for displaced fractures, conservative management may be preferable in high-risk patients. This study reports 6 cases of PPHF after RTSA successfully treated with conservative management incorporating adjunctive teriparatide therapy.MethodsSix patients (mean age, 77.2 years; range, 70–87 years) who developed PPHF after RTSA were treated nonoperatively with daily subcutaneous teriparatide (20 µg) and immobilization using an abduction brace. The mean follow-up duration was 23.8 months (range, 12–36 months). Fractures were classified according to the Wright and Cofield classification system. Radiographic outcomes were assessed using serial plain radiographs. Clinical outcomes were evaluated using the visual analog scale (VAS) pain score, American Shoulder and Elbow Surgeons (ASES) score, and active range of motion.ResultsFracture patterns included type A (n = 1), type B (n = 4), and type C (n = 1). Radiographic union was achieved in all patients (100%) at a mean of 2.7 months (range, 2–4 months). One patient developed malunion. At final follow-up, the mean VAS pain score was 2.2 and the mean ASES score was 69.8. No teriparatide-related adverse events were observed.ConclusionsConservative management with adjunctive teriparatide therapy resulted in reliable radiographic union of PPHF following RTSA in selected patients. In addition to fracture classification, factors such as fracture displacement, angular deformity, implant stability, and patient-specific clinical characteristics should be carefully considered when determining treatment strategy. This approach may represent a viable alternative for elderly patients with substantial medical comorbidities in whom surgical treatment carries considerable risk.Keywords: Reverse total shoulder arthroplasty, Periprosthetic fracture, Parathyroid hormone, Teriparatide, Conservative management Reverse total shoulder arthroplasty (RTSA) has become an established treatment option for elderly patients with rotator cuff tear arthropathy or irreparable massive rotator cuff tear.1,2) With the expansion of indications to include osteoarthritis, fractures, or revision arthroplasty, the volume of RTSA procedures has increased substantially over the past decade.2,3,4) This growth has been accompanied by a corresponding rise in postoperative complications, including implant loosening, instability, infection, and periprosthetic fracture.4,5) Periprosthetic humeral fracture (PPHF) is among the most challenging complications following shoulder arthroplasty, with a reported incidence of approximately 1%–3.5%.6,7) Treatment strategies are primarily guided by fracture location, implant type and stability, and available bone stock.8) The Wright and Cofield classification system categorizes fractures based on their location relative to the stem tip: type A fractures extend proximally, type B fractures are centered at the stem tip, and type C fractures extend distally into the humeral shaft. Traditionally, displaced type A and B fractures are treated surgically, whereas type C fractures are generally managed nonoperatively.7,8) However, treatment decisions are sometimes difficult because these fractures most commonly occur in elderly women with osteoporotic bone.6,7,8) Surgical options for PPHFs include open reduction and internal fixation or revision arthroplasty using a longstem prosthesis.6,7,8,9) However, stable fixation can be technically demanding due to compromised bone stock and impaired healing potential, and it may be associated with substantial perioperative morbidity in elderly patients. Consequently, nonoperative management has been considered a viable alternative in select cases, particularly in patients with stable implants and acceptable fracture alignment.10,11,12,13,14) Nevertheless, previous studies have reported high failure rates following conservative treatment, especially for type B fractures.7,8,9) Recent evidence has highlighted the anabolic effects of parathyroid hormone (PTH) analogs beyond their established role in osteoporosis management.15,16,17) Teriparatide, a recombinant human PTH(1-34), promotes bone formation by intermittently stimulating osteoblastic activity and has been shown to accelerate fracture healing.17) In the context of shoulder arthroplasty, teriparatide has demonstrated potential benefits in promoting healing of acromial stress fractures, tuberosity fixation, and PPHF following RTSA.15,18,19,20,21) However, evidence supporting its use specifically for PPHF after RTSA remains limited and confined to isolated case reports.18,19,21) The purpose of this study was to present a case series of 6 patients with PPHF following RTSA who were successfully treated with conservative management incorporating adjunctive teriparatide therapy, and to explore the potential role of anabolic therapy in expanding indications of nonoperative treatment in this high-risk population. METHODS The study was approved by the Institutional Review Board of Keimyung University Dongsan Hospital (IRB No. 202602014). The requirement for written informed consent was waived because of the retrospective nature of the study. Between 2020 and 2025, 6 patients who were treated with conservative management incorporating teriparatide for PPHFs following RTSA at 4 institutions were retrospectively identified. Medical records were reviewed to obtain demographic data, medical comorbidities, American Society of Anesthesiologists (ASA) physical status classification, details of the index RTSA, fracture characteristics, time to union, clinical outcomes, and complications at final follow-up. Radiographic evaluation included serial plain radiographs and computed tomography (CT) to characterize fracture patterns and assess fracture displacement, angular deformity, callus formation, and implant stability, including evidence of humeral stem loosening or subsidence. Fractures were classified according to the Wright and Cofield classification system.22) All patients were immobilized using an abduction brace for 8 weeks. Range of motion (ROM) exercises were initiated once radiographic evidence of fracture healing with pain improvement was observed. Teriparatide was administered as a daily subcutaneous injection of 20 µg for 3 months following fracture occurrence. The teriparatide dosage was selected based on the standard approved regimen for osteoporosis treatment and previous studies evaluating fracture healing and delayed union. The 3-month treatment duration was empirically determined to support the early fracture healing phase.17,23) Patients were monitored at 4-week intervals initially, with radiographic assessment at each visit; follow-up intervals were subsequently extended to 8–12 weeks as healing progressed. Radiographic union was defined as the presence of bridging callus across the fracture site on at least 3 of 4 cortices on orthogonal radiographs, with disappearance of the fracture line.24) Clinical outcomes included the visual analog scale (VAS) pain score, American Shoulder and Elbow Surgeons (ASES) score, and active ROM, which were evaluated at the final follow-up visit after radiographic union had been confirmed. RESULTS Patient demographics and fracture characteristics are summarized in Table 1. The mean age was 77.2 ± 5.8 years (range, 70–87 years), and all patients were female nonsmokers. The mean T-score for bone mineral density (BMD) was –1.9 ± 0.8 (range, –3.1 to –0.7). Five patients underwent primary RTSA with cementless stems (4 standard stems and 1 short stem), and 1 patient (case 3) underwent RTSA with a cemented standard stem. Table 1Patient Demographic DataCaseAge/sexSideBMD (T-score)Medical comorbidityASA classificationPrimary indication for RTSAImplantStem type & lengthTime from arthroplasty to injury (mo)Wright and Cofield classificationPreexisting stem looseningFollow-up period (mo)187/FLeft–2.6CVAIVCTAEquinoxeCementless short2BNo30274/FRight–1.8HTN, HL, asthmaIIIIMRCTSMRCementless standard1BNo20370/FLeft–0.7HTN, DMIIICTASMRCemented standard0CNo12480/FRight–1.8DMIIIPTOAEquinoxeCementless standard40BYes36575/FLeft–3.1Angina pectoris, dementiaIIIFixation failure for PHFTMCementless standard88BYes12677/FRight–1.6Graves’ disease, HTN, HLIIICTACoralisCementless standard3ANo33BMD: bone mineral density, ASA: American Society of Anesthesiologists, RTSA: reverse total shoulder arthroplasty, CTA: cuff tear arthropathy, HTN: hypertension, HL: hyperlipidemia, IMRCT: irreparable massive rotator cuff tear, DM: diabetes mellitus, PTOA: post-traumatic osteoarthritis, PHF: proximal humerus fracture, CVA: cerebrovascular accident. Patient Demographic Data BMD: bone mineral density, ASA: American Society of Anesthesiologists, RTSA: reverse total shoulder arthroplasty, CTA: cuff tear arthropathy, HTN: hypertension, HL: hyperlipidemia, IMRCT: irreparable massive rotator cuff tear, DM: diabetes mellitus, PTOA: post-traumatic osteoarthritis, PHF: proximal humerus fracture, CVA: cerebrovascular accident. PPHF occurred at a mean of 22.3 months postoperatively (range, 0–88 months). Five fractures occurred after low-energy falls, and 1 fracture (case 3) was suspected to be an unrecognized intraoperative fracture that became evident postoperatively. According to the ASA physical status classification, there was type III in 5 patients and type IV in 1 patient. According to the Wright and Cofield classification, there were 1 type A fracture (16.7%), 4 type B fractures (66.7%), and 1 type C fracture (16.7%). The mean follow-up period after PPHFs was 23.8 months (range, 12–36 months). Radiographic union was achieved in all 6 cases (100%) at a mean of 2.7 months (range, 2–4 months). Serial radiographs demonstrated progressive callus formation and maintenance of acceptable fracture alignment without significant progression of displacement or angular deformity during follow-up. Two patients (cases 4 and 5) demonstrated preexisting humeral stem loosening at initial evaluation. Case 4 showed mild stem subsidence during follow-up but maintained stable fracture healing without progressive loosening, whereas case 5 achieved fracture union despite residual malalignment. Notably, 4 patients (cases 1, 2, 4, and 5) with type B fractures—traditionally considered candidates for surgical treatment—achieved union with conservative management. Case 1 achieved radiographic union at 2 months with callus formation despite having the lowest BMD (T-score, –2.6) (Fig. 1). Case 2 with a displaced fracture around the stem tip achieved successful union at 2 months with restoration of favorable functional outcomes (Fig. 2). Case 4 with preexisting humeral stem loosening achieved solid union at 3 months with favorable clinical outcome despite radiographic evidence of stem subsidence. Case 5, who had dementia and preexisting stem loosening, achieved radiographic union at 3 months but healed with malunion (Fig. 3). Although radiographic malunion was observed, the patient maintained acceptable clinical outcomes without progressive pain or need for revision surgery. Case 1 (87-year-old woman). (A) Plain radiograph at initial trauma shows Wright and Cofield type B periprosthetic humeral fracture. (B) Plain radiograph after 4 weeks shows extensive callus formation. (C) Plain radiograph after 8 weeks shows radiographic union. (D) Plain radiograph after 12 months shows complete healing of the fracture. Case 2 (74-year-old woman). (A) Plain radiograph at initial trauma shows Wright and Cofield type B periprosthetic humeral fracture. (B) Plain radiograph after 4 weeks shows some callus formation. (C) Plain radiograph after 8 weeks shows radiographic union. (D) Plain radiograph after 12 months shows complete healing of the fracture. Case 5 (75-year-old woman). (A) Plain radiograph at initial trauma shows Wright and Cofield type B periprosthetic humeral fracture with preexisting humeral stem loosening. (B) Plain radiograph after 4 weeks shows some callus formation. (C) Plain radiograph after 3 months shows radiographic union. (D) Plain radiograph after 6 months shows malunited fracture healing. At final follow-up, the mean VAS score was 2.2 ± 2.1, and the mean ASES score was 69.8 ± 21.7. Mean final forward flexion was 118.3° ± 20.4°, abduction was 96.7° ± 16.3°, external rotation was 50° ± 12.6°, and internal rotation was to the third lumbar vertebra level (Table 2). Table 2Radiological and Clinical OutcomesCaseTime to union (mo)Final VAS pain scoreFinal ASES scoreFinal forward flexion (°)Final abduction (°)Final external rotation (°)Final internal rotationComplication1263012010060T12None2219513012060L5None3237211010060SacrumNone432751109040L5Stem subsidence53067907030L5Malunion6418015010050T10NoneVAS: visual analog scale, ASES: American Shoulder and Elbow Surgeons, T: thoracic vertebra, L: lumbar vertebra. Radiological and Clinical Outcomes VAS: visual analog scale, ASES: American Shoulder and Elbow Surgeons, T: thoracic vertebra, L: lumbar vertebra. DISCUSSION The principal finding of the present study is that conservative treatment incorporating adjunctive teriparatide therapy resulted in reliable radiographic union in all 6 cases of PPHF after RTSA, including fractures that are traditionally considered candidates for surgical intervention. All 6 patients achieved union at a mean of 2.7 months, including 4 patients with type B fractures. Notably, 2 patients with type B fractures and preexisting stem loosening (cases 4 and 5)—who would conventionally be indicated for revision RTSA—achieved successful bone union with conservative management using teriparatide. Historically, treatment algorithms for PPHF have emphasized fracture location, implant stability, and fracture displacement as the primary determinants of management.7) Type C fractures are generally considered amenable to nonoperative treatment, whereas type A and B fractures—particularly those with displacement or proximity to the stem tip—are often managed surgically because of concerns regarding delayed union, nonunion, or progressive humeral stem loosening.7,8) A systematic review and meta-analysis by Tansey et al.7) reported that nonoperatively treated PPHFs were associated with higher complication rates and an increased risk of malunion. In particular, type B fractures demonstrated a failure rate of up to 57% following nonoperative treatment, leading the authors to recommend careful patient counseling regarding the likelihood of additional surgery.7) Wolf et al.9) reported that conservative treatment of type B fractures was insufficient to reliably achieve union, especially in short oblique or transverse fracture patterns. Despite these concerns, accumulating evidence suggests that selected PPHFs with stable implants may achieve satisfactory outcomes with conservative management, particularly in patients for whom surgical risks outweigh potential benefits.10,11,12,13,14) In the present study, 4 of 6 fractures were classified as type B, including cases with notable displacement. Nevertheless, all fractures achieved solid radiographic union with immobilization and adjunctive teriparatide therapy. Implant stability is generally regarded as a critical prerequisite for successful nonoperative management of PPHF. In this series, 2 patients demonstrated preexisting humeral stem loosening on plain radiographs and CT. However, conservative treatment was selected because neither patient had pre-fracture symptoms related to loosening, and both were elderly, low-demand individuals with significant medical comorbidities or cognitive impairment. These cases suggest that radiographic evidence of stem loosening alone should not necessarily mandate surgical intervention in carefully selected patients. Taken together, these findings support the concept that fracture location or implant stability alone should not serve as the sole determinants of treatment strategy. Instead, patient-specific factors—including age, bone quality, functional demand, comorbidities, and anesthetic risk—should play a critical role in clinical decision-making. Teriparatide, a recombinant PTH(1-34) analog, exerts anabolic effects on bone through intermittent stimulation of osteoblastic activity, thereby promoting bone formation and accelerating callus formation.15,16,17) It is currently approved for the treatment of severe osteoporosis in patients at high risk for fracture. The standard dosage of 20 µg daily used in the present study was selected based on the approved osteoporosis treatment regimen and previous fracture healing studies. Although treatment duration has varied among studies, short-term administration for 3 to 6 months has been most commonly reported in fracture healing applications.17,23) Recent systematic reviews and meta-analyses have suggested that teriparatide may accelerate fracture healing and improve union rates, particularly in delayed unions and long bone fractures.17,23) However, the overall level of evidence remains limited because most available studies are retrospective, observational, or case-based, and high-quality prospective studies regarding periprosthetic fractures are still lacking. Previous studies have reported favorable effects of teriparatide in delayed unions, nonunions, stress fractures, and periprosthetic fractures.15,16,17,18,19,20,21) Several case reports have additionally suggested potential benefits of teriparatide for fracture healing following RTSA, including acromial stress fractures, tuberosity healing, and PPHFs.18,19,20,21) In the present study, the daily subcutaneous dose of 20 µg of teriparatide was selected based on its established anabolic effects on bone and its widely recognized role in promoting fracture healing and stimulating osteoblastic activity, as supported by existing literature.17,23) Studies have shown that fractures treated with 20 µg of teriparatide exhibit early signs of union with significant callus formation. This dose is a standard and effective regimen utilized in various orthopedic contexts to enhance bone formation and accelerate healing, particularly in osteoporotic fractures. All 6 patients achieved radiographic union at a mean of 2.7 months, which is comparable to—or shorter than—the 3 to 7 months typically reported for conservatively treated PPHF.12,13,14) Importantly, successful union was observed even in patients with low BMD and in fractures occurring near the stem tip, where biological healing potential is often compromised. These findings suggest that teriparatide may serve as a valuable adjunct to conservative management by enhancing the biological environment for fracture healing in high-risk patients. Several studies have reported favorable outcomes with nonoperative treatment of selected PPHFs. Kim et al.12) demonstrated that functional bracing could achieve union even in displaced PPHFs in elderly patients with osteopenic bone. Ragusa et al.13) reported successful nonoperative outcomes in 4 patients with stable implants, but noted a 1-year mortality rate of 50%, underscoring the importance of minimizing surgical intervention in these frail patients. Dukan et al.10) proposed that nonoperative treatment should be guided by the absence of implant loosening and tolerance for potential malunion, regardless of fracture classification. In the present study, 1 patient (case 1) experienced functional decline at final follow-up, which was likely attributable to advanced age and cognitive impairment following a cerebrovascular accident rather than fracture-related factors. These findings highlight that although radiographic union can be reliably achieved, functional outcomes remain influenced by patient-related factors beyond fracture healing alone. Overall, the results of this study suggest that adjunctive teriparatide therapy may enhance fracture healing and potentially expand the indications for nonoperative management of PPHF in carefully selected, high-risk patients. This study has several limitations. First, the retrospective multicenter design and small sample size inherent to a case series limit the generalizability of the findings. Second, the absence of a control group precludes definitive conclusions regarding the independent effect of teriparatide compared with immobilization alone. Third, although teriparatide has demonstrated promising anabolic effects in fracture healing, high-level evidence supporting its efficacy in long bone or periprosthetic fractures remains limited. Finally, the relatively short follow-up duration may not fully capture long-term functional outcomes or late complications. Future prospective comparative studies with large cohorts and longer follow-up are needed to define optimal patient selection criteria and to determine whether teriparatide provides additional benefit beyond immobilization alone. In conclusion, conservative management with adjunctive teriparatide therapy resulted in reliable radiographic union of PPHF following RTSA in selected patients. In addition to fracture classification, factors such as fracture displacement, angular deformity, implant stability, and patient-specific clinical characteristics should be carefully considered when determining treatment strategy. This approach may represent a viable alternative for elderly patients with substantial medical comorbidities in whom surgical treatment carries considerable risk. ACKNOWLEDGEMENTS We thank Eun-Ji Jeon and Ye-Ji Kim for their support with data collection. Footnotes CONFLICT OF INTEREST: Jong Pil Yoon and Chul-Hyun Cho are editorial board members of the journal but were not involved in the peer reviewer selection, evaluation, or decision process of this article. No other potential conflicts of interest relevant to this article were reported. References